DSCO could bounce but the company is in trouble. Their drug they had been concentrating on is at least 1 - 2 years from another FDA approval cycle. shelf life problem
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.